About Ligand Pharmaceuticals (NASDAQ:LGND)
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio60.57
Forward P/E Ratio36.81
Sales & Book Value
Annual Sales$141.10 million
Price / Sales23.40
Cash Flow$3.5112 per share
Price / Cash44.35
Book Value$18.94 per share
Price / Book8.22
EPS (Most Recent Fiscal Year)$2.57
Net Income$12.55 million
Return on Equity14.44%
Return on Assets8.65%
Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions
What is Ligand Pharmaceuticals' stock symbol?
Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."
How were Ligand Pharmaceuticals' earnings last quarter?
Ligand Pharmaceuticals (NASDAQ:LGND) released its earnings results on Wednesday, February, 21st. The biotechnology company reported $1.31 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.19 by $0.12. The biotechnology company had revenue of $50.50 million for the quarter, compared to analysts' expectations of $49.39 million. Ligand Pharmaceuticals had a net margin of 8.90% and a return on equity of 14.44%. The company's quarterly revenue was up 32.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.25 earnings per share. View Ligand Pharmaceuticals' Earnings History.
When is Ligand Pharmaceuticals' next earnings date?
What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?
Ligand Pharmaceuticals issued an update on its FY18 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of $4.22 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.91. The company issued revenue guidance of $164 million, compared to the consensus revenue estimate of $166.87 million.
What price target have analysts set for LGND?
5 brokers have issued 1 year target prices for Ligand Pharmaceuticals' stock. Their forecasts range from $105.00 to $200.00. On average, they expect Ligand Pharmaceuticals' stock price to reach $159.00 in the next twelve months. View Analyst Ratings for Ligand Pharmaceuticals.
What are Wall Street analysts saying about Ligand Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Ligand’s earnings and revenues beat estimates in fourth-quarter 2017. The company’s captisol formulation technology has resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Also, with regard to Ligand’s internal pipeline, there are several candidates in development that could bring in future licensing opportunities. Additionally, the company’s entry into the Medical Devices Segment with the buyout of multiple programs owned by CorMatrix is encouraging. Shares of Ligand have outperformed the broader industry in the past year. However, the company derives a substantial portion of its revenues from royalties associated with the sales of Promacta and Kyprolis. Any setback related to these two products could leave a substantial impact. Moreover, Ligand’s dependence on a single supplier to obtain Captisol is concerning." (2/28/2018)
- 2. HC Wainwright analysts commented, "Kyprolis Beats; Recent and Anticipated Label Expansions Represent Revenue Inflection Points Kyprolis quickly approaching blockbuster status. Yesterday, partner Amgen (AMGN; not rated) announced 4Q17 and 2017 Kyprolis revenue of $227M and $835M, respectively, compared with our estimates of $220M (consensus $225M) and $828M. As Kyprolis approaches blockbuster status, considering certain factors we think should be able to easily push it over the edge, and they include: 1) recent FDA approval of sNDA based on ENDEAVOR overall survival data; 2) recent CHMP positive opinion to include updated overall survival from ENDEAVOR on label this year in the E.U.; and 3) recent submission of sNDA to FDA and a variation to the marketing authorization to the EMA, both based on the overall survival benefit from the ASPIRE study (actions expected this year). Upcoming milestones and key programs underway: 2018 initial visibility from recent launch of Baxdela for serious skin infections." (2/2/2018)
Who are some of Ligand Pharmaceuticals' key competitors?
Some companies that are related to Ligand Pharmaceuticals include Grifols (GRFS), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Merck Group (MKGAF), Genmab As (GNMSF), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), BeiGene (BGNE), Alkermes (ALKS), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT) and Dr. Reddy's Laboratories (RDY).
Who are Ligand Pharmaceuticals' key executives?
Ligand Pharmaceuticals' management team includes the folowing people:
- Mr. John L. Higgins, Chief Exec. Officer and Exec. Director (Age 48)
- Mr. Matthew W. Foehr, Pres and Chief Operating Officer (Age 45)
- Mr. Matthew Korenberg, Exec. VP of Fin., CFO & Principal Accounting Officer (Age 43)
- Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 49)
- Ms. Audrey Warfield-Graham, VP of HR
Has Ligand Pharmaceuticals been receiving favorable news coverage?
News stories about LGND stock have trended somewhat positive this week, according to Accern Sentiment. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ligand Pharmaceuticals earned a media sentiment score of 0.01 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 45.02 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Ligand Pharmaceuticals' major shareholders?
Ligand Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include
KNOTT DAVID M
(4.10%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Melanie J Herman, Stephen L Sabba and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.
How do I buy shares of Ligand Pharmaceuticals?
Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ligand Pharmaceuticals' stock price today?
One share of LGND stock can currently be purchased for approximately $156.88.
How big of a company is Ligand Pharmaceuticals?
Ligand Pharmaceuticals has a market capitalization of $3.55 billion and generates $141.10 million in revenue each year. The biotechnology company earns $12.55 million in net income (profit) each year or $2.57 on an earnings per share basis. Ligand Pharmaceuticals employs 39 workers across the globe.
How can I contact Ligand Pharmaceuticals?
Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]
MarketBeat Community Rating for Ligand Pharmaceuticals (LGND)MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ligand Pharmaceuticals (NASDAQ:LGND) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Ligand Pharmaceuticals (NASDAQ LGND) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.30%
Ligand Pharmaceuticals (NASDAQ LGND) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|4/2/2018||John W Kozarich||Director||Sell||2,500||$160.43||$401,075.00|| |
|3/12/2018||Stephen L Sabba||Director||Sell||622||$180.73||$112,414.06||26,363|| |
|3/9/2018||Jason Aryeh||Director||Sell||7,500||$175.73||$1,317,975.00||58,625|| |
|3/5/2018||John L Lamattina||Director||Sell||3,335||$160.90||$536,601.50||24,291|| |
|2/27/2018||Todd C Davis||Director||Sell||17,170||$152.37||$2,616,192.90||65,898|| |
|2/23/2018||Jason Aryeh||Director||Sell||3,417||$155.00||$529,635.00||58,625|| |
|2/23/2018||Matthew W Foehr||COO||Sell||5,444||$152.98||$832,823.12||95,835|| |
|2/15/2018||John L Higgins||CEO||Sell||9,000||$157.03||$1,413,270.00||102,700|| |
|1/24/2018||John L Higgins||CEO||Sell||22,500||$165.00||$3,712,500.00||111,700|| |
|1/19/2018||John L Higgins||CEO||Sell||28,099||$153.70||$4,318,816.30||162,299|| |
|1/10/2018||John W Kozarich||Director||Sell||2,500||$145.00||$362,500.00||33,149|| |
|12/20/2017||Stephen L Sabba||Director||Sell||925||$137.25||$126,956.25||26,985|| |
|11/17/2017||Matthew E Korenberg||VP||Sell||6,559||$142.63||$935,510.17||8,147|| |
|11/16/2017||John L Higgins||CEO||Sell||5,269||$142.53||$750,990.57||143,542|| |
|11/16/2017||John W Kozarich||Director||Sell||5,000||$141.71||$708,550.00||35,649|| |
|9/5/2017||John L Higgins||CEO||Sell||5,000||$130.00||$650,000.00||144,171|| |
|8/23/2017||Jason Aryeh||Director||Sell||2,000||$127.99||$255,980.00||59,625|| |
|8/9/2017||Charles S Berkman||VP||Sell||18,625||$126.96||$2,364,630.00||24,423|| |
|8/9/2017||Matthew W Foehr||Insider||Sell||6,100||$127.51||$777,811.00||101,020|| |
|8/8/2017||John L Higgins||CEO||Sell||5,483||$125.00||$685,375.00||144,654|| |
|6/21/2017||John L Higgins||CEO||Sell||4,666||$120.00||$559,920.00||143,837|| |
|6/9/2017||John L Higgins||CEO||Sell||12,000||$114.87||$1,378,440.00||151,171|| |
|5/12/2017||Jason Aryeh||Director||Sell||37,247||$110.76||$4,125,477.72||58,959|| |
|5/12/2017||Matthew W Foehr||Insider||Sell||5,621||$112.20||$630,676.20||98,341|| |
|3/20/2017||John L Higgins||CEO||Sell||4,000||$109.10||$436,400.00||139,171|| |
|3/2/2017||Matthew W Foehr||Insider||Sell||6,879||$103.39||$711,219.81||97,599|| |
|2/28/2017||Jason Aryeh||Director||Sell||32,000||$106.35||$3,403,200.00||58,959|| |
|11/25/2016||Jason Aryeh||Director||Sell||18,479||$107.31||$1,982,981.49||58,959|| |
|11/18/2016||Jason Aryeh||Director||Sell||6,330||$105.28||$666,422.40||58,959|| |
|9/22/2016||John L Higgins||CEO||Sell||3,000||$117.34||$352,020.00||122,664|| |
|9/7/2016||John W Kozarich||Director||Sell||1,000||$115.00||$115,000.00||39,983|| |
|9/1/2016||John W Kozarich||Director||Sell||1,666||$105.40||$175,596.40||40,783|| |
|8/1/2016||John W Kozarich||Director||Sell||1,000||$137.57||$137,570.00||41,783|| |
|7/1/2016||John W Kozarich||Director||Sell||1,000||$121.40||$121,400.00||42,883|| |
|6/1/2016||John W Kozarich||Director||Sell||1,000||$117.42||$117,420.00||43,361|| |
|5/18/2016||Melanie J Herman||Director||Sell||334||$120.50||$40,247.00||3,297|| |
|5/6/2016||Jason Aryeh||Director||Sell||25,000||$119.20||$2,980,000.00||58,337|| |
|5/2/2016||John W Kozarich||Director||Sell||1,000||$121.57||$121,570.00||43,911|| |
|4/6/2016||John W Kozarich||Director||Sell||5,000||$115.00||$575,000.00||44,711|| |
|3/17/2016||Matthew W Foehr||COO||Sell||6,400||$96.70||$618,880.00||83,062|| |
|3/8/2016||Jason Aryeh||Director||Sell||6,129||$101.18||$620,132.22||58,337|| |
|3/7/2016||John L Higgins||CEO||Sell||10,833||$102.47||$1,110,057.51||120,220|| |
|1/20/2016||John W. Kozarich||Director||Sell||1,666||$94.94||$158,170.04||49,711|| |
|11/11/2015||Melanie J. Herman||Director||Sell||7,719||$101.00||$779,619.00||3,151|| |
|8/17/2015||David M Knott||Director||Sell||4,000||$95.98||$383,920.00|| |
|8/13/2015||David M Knott||Director||Sell||49,800||$96.26||$4,793,748.00|| |
|7/10/2015||Charles S Berkman||VP||Sell||14,067||$99.14||$1,394,602.38|| |
|6/26/2015||Matthew W Foehr||COO||Sell||12,500||$100.97||$1,262,125.00|| |
|6/22/2015||Matthew W Foehr||COO||Sell||23,046||$96.45||$2,222,786.70|| |
|6/10/2015||Melanie J Herman||CFO||Sell||4,125||$93.50||$385,687.50|| |
|6/9/2015||John L Higgins||CEO||Sell||10,000||$92.88||$928,800.00|| |
|6/4/2015||Jason Aryeh||Director||Sell||1,640||$92.68||$151,995.20|| |
|5/20/2015||Jason Aryeh||Director||Sell||9,240||$87.34||$807,021.60|| |
|5/14/2015||Nishan M Desilva||CFO||Sell||68,363||$83.91||$5,736,339.33|| |
|3/19/2015||Sunil Patel||Director||Sell||4,591||$74.42||$341,662.22|| |
|2/10/2015||Nishan M Desilva||VP||Sell||2,300||$56.34||$129,582.00|| |
|10/15/2014||John W Kozarich||Director||Buy||2,000||$45.68||$91,360.00|| |
|10/9/2014||Jason Aryeh||Director||Buy||11,000||$42.99||$472,890.00|| |
|8/15/2014||John L Higgins||CEO||Buy||1,000||$54.97||$54,970.00|| |
|6/9/2014||Melanie J Herman||Director||Sell||1,100||$69.68||$76,648.00|| |
|5/27/2014||Charles S Berkman||VP||Sell||7,166||$66.90||$479,405.40|| |
|3/25/2014||Bvf Partners P/Il||Insider||Sell||78,226||$70.09||$5,482,860.34|| |
|3/19/2014||Todd Davis||Director||Sell||7,500||$79.57||$596,775.00||32,536|| |
|3/18/2014||John Lamattina||Director||Sell||5,000||$78.83||$394,150.00||21,356|| |
|2/20/2014||Bvf Partners P/Il||major shareholder||Sell||422,900||$73.81||$31,214,249.00|| |
|2/18/2014||David Knott||Director||Sell||41,900||$75.71||$3,172,249.00||63,743|| |
|2/14/2014||Jason Aryeh||Director||Sell||40,320||$76.44||$3,082,060.80||31,243|| |
|2/14/2014||Matthew Foehr||COO||Sell||22,500||$79.54||$1,789,650.00||53,457|| |
|12/12/2013||Matthew Foehr||COO||Sell||6,000||$53.40||$320,400.00||44,929|| |
|12/6/2013||John Sharp||CFO||Sell||6,000||$56.08||$336,480.00||17,667|| |
|10/18/2013||John L Higgins||CEO||Sell||10,000||$55.00||$550,000.00|| |
|9/23/2013||Bvf Partners P/Il||major shareholder||Sell||359,023||$44.50||$15,976,523.50|| |
|9/12/2013||David Knott||Director||Sell||160,000||$46.78||$7,484,800.00||63,743|| |
|8/30/2013||Charles Berkman||VP||Sell||28,323||$47.54||$1,346,475.42||26,936|| |
|8/16/2013||Charles Berkman||VP||Sell||14,583||$42.63||$621,673.29||17,928|| |
|8/16/2013||John Higgins||CEO||Sell||10,000||$42.85||$428,500.00||116,581|| |
|8/16/2013||John Sharp||CFO||Sell||7,500||$42.75||$320,625.00||24,166|| |
|6/28/2013||Matthew W Foehr||COO||Buy||1,059||$17.36||$18,384.24|| |
|5/10/2013||Charles S Berkman||VP||Sell||4,000||$26.66||$106,640.00|| |
|1/23/2013||Bvf Partners L P/Il||Major Shareholder||Buy||39,600||$19.78||$783,288.00|| |
|12/14/2012||Bvf Partners L P/Il||Major Shareholder||Buy||5,386||$18.63||$100,341.18|| |
|12/6/2012||Bvf Partners L P/Il||Major Shareholder||Buy||50,100||$17.94||$898,794.00|| |
|12/5/2012||John L Higgins||CEO||Buy||2,000||$18.03||$36,060.00|| |
|10/31/2012||Bvf Partners L P/Il||Major Shareholder||Buy||16,591||$15.19||$252,017.29|| |
|8/29/2012||David M Knott||Director||Buy||2,743||$16.36||$44,875.48|| |
Ligand Pharmaceuticals (NASDAQ LGND) News Headlines
Ligand Pharmaceuticals (NASDAQ:LGND) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Ligand Pharmaceuticals (NASDAQ:LGND) Income Statement, Balance Sheet and Cash Flow Statement
Ligand Pharmaceuticals (NASDAQ LGND) Stock Chart for Wednesday, April, 25, 2018